EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities

Nicoletta Basilico iD, Silvia Parapini iD, Sarah D'Alessandro iD, Paola Misiano iD, Sergio Romeo iD, Giulio Dondio iD, Vanessa Yardley, Livia Vivas, Shereen Nasser, Laurent Rénia iD, Bruce M Russell, Rossarin Suwanarusk und 3 weitere

Biomolecules · 2023

DOI: 10.3390/biom13050836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Nicoletta Basilico und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche (DiSBIOC), Università Degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy. Hauptthemen laut MEDLINE: Antimalarials, Quinolines, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, 6th Framework Programme of the European Community, Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN) Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 4-aminoquinoline drugs, such as chloroquine (CQ), amodiaquine or piperaquine, are still commonly used for malaria treatment, either alone (CQ) or in combination with artemisinin derivatives. We previously described the excellent in vitro activity of a novel pyrrolizidinylmethyl derivative of 4-amino-7-chloroquinoline, named MG3, against P. falciparum drug-resistant parasites. Here, we report the optimized and safer synthesis of MG3, now suitable for a scale-up, and its additional in vitro and in vivo characterization. MG3 is active against a panel of P. vivax and P. falciparum field isolates, either alone or in combination with artemisinin derivatives. In vivo MG3 is orally active in the P. berghei, P. chabaudi, and P. yoelii models of rodent malaria with efficacy comparable, or better, than that of CQ and of other quinolines under development. The in vivo and in vitro ADME-Tox studies indicate that MG3 possesses a very good pre-clinical developability profile associated with an excellent oral bioavailability, and low toxicity in non-formal preclinical studies on rats, dogs, and non-human primates (NHP). In conclusion, the pharmacological profile of MG3 is in line with those obtained with CQ or the other quinolines in use and seems to possess all the requirements for a developmental candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsQuinolinesMalariaMalaria, FalciparumArtemisininsRatsAnimalsDogsPlasmodium falciparumChloroquine

Stichwörter der Autor:innen

4-aminoquinolinesdrug discoverymalaria

Substanzen

AntimalarialsChloroquineQuinolinesArtemisinins

Autor:innen und Institutionen

  • Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche (DiSBIOC), Università Degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy.
  • Dipartimento di Scienze Biomediche per la Salute, Università Degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy.
  • Dipartimento di Scienze Farmacologiche e Biomolecolari (DISFEB), Università Degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy.
  • Dipartimento di Scienze Farmaceutiche (DISFARM), Università Degli Studi di Milano, Via Mangiagalli 25, 20133 Milan, Italy.
  • Aphad Srl, Via della Resistenza 65, Buccinasco, 20090 Milan, Italy.
  • Department of Immunology Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London WC1E 7HT, UK.

ORCID-Profile: Nicoletta Basilico, Silvia Parapini, Sarah D'Alessandro, Paola Misiano, Sergio Romeo, Giulio Dondio, Laurent Rénia, Anna Sparatore, Donatella Taramelli

Förderung

  • Wellcome Trust
  • 6th Framework Programme of the European Community
  • Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN) Projects
  • Global Health Program of the Bill & Melinda Gates Foundation
  • Ministero degli Affari Esteri e della Cooperazione Internazionale
  • A*STAR Infectious Disease labs
  • orizontal Programme on Infectious Diseases under the Agency for Science, Technology and Research
  • SMRU supported by The Wellcome Trust of Great Britain

Zitieren

APA

Basilico, N., Parapini, S., D'Alessandro, S., Misiano, P., Romeo, S., Dondio, G., Yardley, V., Vivas, L., Nasser, S., Rénia, L., Russell, B. M., Suwanarusk, R., Nosten, F., Sparatore, A., & Taramelli, D. (2023). Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities. Biomolecules. https://doi.org/10.3390/biom13050836

Vancouver

Basilico N, Parapini S, D'Alessandro S, Misiano P, Romeo S, Dondio G, et al. Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities. Biomolecules. 2023. doi:10.3390/biom13050836

BibTeX
@article{Basilico2023,
  author = {Basilico, Nicoletta and Parapini, Silvia and D'Alessandro, Sarah and Misiano, Paola and Romeo, Sergio and Dondio, Giulio and Yardley, Vanessa and Vivas, Livia and Nasser, Shereen and Rénia, Laurent and Russell, Bruce M and Suwanarusk, Rossarin and Nosten, François and Sparatore, Anna and Taramelli, Donatella},
  title = {Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13050836}
}
Kostenlos starten →